Sponsor Directory

Pfizer clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3279

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Acute Lymphoblastic Leukemia
Interventions: Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: San Diego, California • Memphis, Tennessee

Conditions: Lung Cancer
Interventions: Binimetinib, Palbociclib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Plantation, Florida • Norfolk, Virginia

Conditions: Multiple Myeloma
Interventions: Elranatamab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 35
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fort Collins, Colorado + 20 more

Conditions: COVID-19 (Coronavirus Disease 2019)
Interventions: nirmatrelvir-ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 131,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Placebo, PF-07258669; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years to 89 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlantis, Florida • Bradenton, Florida + 7 more

Conditions: Obesity
Interventions: PF-07976016, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Anaheim, California • San Diego, California • Aurora, Colorado + 19 more

Conditions: HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
Interventions: TG4001, Avelumab; Biological · Drug
Lead sponsor: Transgene; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Metastatic Prostate Cancer
Interventions: Provider-level and patient education at end of study, Provider-level and patient-level; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Respiratory Syncytial Viruses
Interventions: ABRYSVO Vaccination; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 0 Months to 6 Months
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Zavegepant 10 mg IN; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity and Overweight
Interventions: (Part C) MET097, (Part C) Placebo; Biological
Lead sponsor: Metsera, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Anaheim, California • Cypress, California • Overland Park, Kansas

About this Pfizer sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Pfizer is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pfizer trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Pfizer clinical trials

Filter and sort this sponsor

Live official records

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Physician- and Patient-based Barriers to NGS Testing

Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania

A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling

This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

About this Pfizer sponsor directory page